New therapy developed by RTP biotech startup offers hope to sufferers of Crohn’s disease, colitis
The study, conducted by Gusto Global and UNC-Chapel Hill scientists, demonstrated that Gusto Global’s novel community of bacteria prevented and treated chronic immune-mediated colitis in “humanized” mouse models.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed